By Greg Brozeit | Posted - Sep 8th, 2021

 

 

 

 

The International Myeloma Workshop Opens in Vienna

“Just imagine what we will see as we move these therapies up front,” pondered International Myeloma Society (IMS) President Nikhil Munshi about recently approved drugs moving up eventually to newly diagnosed patients as he opened the International Myeloma Workshop (IMW) in Vienna, Austria on September 8, 2021.

Diagnostic tests will also become better and more refined in disease management, leading Dr. Munshi to conclude that “MRD and expanded MRD will lead to a cure.”

Munshi believes that as many as 25% of patients today may be cured, but no tests exit to verify this estimate. “There’s a portion of patients that are not relapsing and we’re building on that.”

Noting the fundamental changes that have taken place since the last IMW in Boston, Dr. Munshi concluded that myeloma advances in the past decade and a half have been astounding. “Progress has truly been breathtaking” and has translated into better outcomes for myeloma patients everywhere, including:

  • Genetic characteristics linked to specific therapies
  • Factors that affect progression of high-risk disease
  • Identifying a “good” risk group with long survival prognoses
  • New technology in diagnostics and gene manipulation to improve therapy
  • Drug pathway resistance
  • The role of tests like MRD to speed up drug approval and create cures

This increased activity and knowledge is already paying dividends in the clinic. In addition to five new drug approvals in the past two years, Dr. Munshi cited the roles that MRD and expanded MRD as well as “the future promise of CAR T” therapy.

What’s the difference between the International Myeloma Workshop (IMW) and the American Society of Hematology (ASH) meetings?  Simply put, IMW looks at the the actual state of myeloma treatment today; ASH is mostly forward-looking, a time to report on studies about how things might change.

IMW is biannual, conducted by the International Myeloma Society (IMS) and attended by professionals who primarily treat or work with myeloma patients.  ASH is the annual professional meeting for all hematological conditions, myeloma being one of many topics covered.

Check the HealthTree Foundation website for more articles from this year’s IMW, which continues through September 11.

 
Greg Brozeit
About the Author

Greg Brozeit - Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years. In the first half of his time with the IMF, he inaugurated the public policy advocacy program, patient support group outreach and conceived the regional community workshop program. In the latter half, he directed IMF Europe, organizing more than 100 physician and patient education programs. Prior to working in myeloma, Greg was a program and project director for the Center for Civic Education, the Alliance for Aging, and he also served as a legislative aide for U.S. Senator J. Bennett Johnston (D-LA). He began his career as an upper school teacher and boys soccer coach in New Orleans, LA. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS


Thanks to our Myeloma Crowd Community sponsors:

.                         .